CDKN2A and Leigh syndrome: The loss of p16 expression has been shown to be present in 30% of tumors with MLH1 promoter hypermethylation but in none of the tumors from patients with LS, suggesting that p16 immunochemistry may be used as a surrogate marker for MLH1 hypermethylation [289,290].